Acura Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone847-705-7709
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$410,000.00
Profitability
Miscellaneous
Employees14
Next Earnings Date11/26/2019 (Estimated)
OptionableNot Optionable
Acura Pharmaceuticals (OTCMKTS:ACUR) Frequently Asked Questions
What is Acura Pharmaceuticals' stock symbol?
Acura Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ACUR."
How were Acura Pharmaceuticals' earnings last quarter?
Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) announced its quarterly earnings data on Tuesday, August, 14th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. The specialty pharmaceutical company had revenue of $0.08 million for the quarter. View Acura Pharmaceuticals' Earnings History.
When is Acura Pharmaceuticals' next earnings date?
Has Acura Pharmaceuticals been receiving favorable news coverage?
Media headlines about ACUR stock have been trending negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Acura Pharmaceuticals earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Acura Pharmaceuticals.
Who are some of Acura Pharmaceuticals' key competitors?
Some companies that are related to Acura Pharmaceuticals include Aerpio Pharmaceuticals (ARPO), Provectus Biopharmaceuticals (PVCT), Sierra Oncology (SRRA), ContraFect (CFRX), Intec Pharma (NTEC), Acerus Pharmaceuticals (ASPCF), OncoSec Medical (ONCS), Acerus Pharmaceuticals (TRLPF), Ceapro (CRPOF), Mateon Therapeutics (MATN), ProPhase Labs (PRPH), DiaMedica Therapeutics (DMAC), Pain Therapeutics (PTIE), Kazia Therapeutics (KZIA) and Cassava Sciences (SAVA).
What other stocks do shareholders of Acura Pharmaceuticals own?
Who are Acura Pharmaceuticals' key executives?
Acura Pharmaceuticals' management team includes the folowing people:
- Mr. Robert B. Jones, CEO, Pres & Director (Age 60)
- Mr. Peter A. Clemens, Sr. VP, CFO & Sec. (Age 66)
- Mr. James F. Emigh, VP of Corp. Devel. (Age 63)
- Mr. Robert A. Seiser Ph.D., VP, Treasurer & Corp. Controller (Age 55)
How do I buy shares of Acura Pharmaceuticals?
Shares of ACUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Acura Pharmaceuticals' stock price today?
One share of ACUR stock can currently be purchased for approximately $0.30.
How big of a company is Acura Pharmaceuticals?
What is Acura Pharmaceuticals' official website?
How can I contact Acura Pharmaceuticals?
Acura Pharmaceuticals' mailing address is 616 N. NORTH COURT SUITE 120, PALATINE IL, 60067. The specialty pharmaceutical company can be reached via phone at 847-705-7709 or via email at [email protected]
MarketBeat Community Rating for Acura Pharmaceuticals (OTCMKTS ACUR)
MarketBeat's community ratings are surveys of what our community members think about Acura Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
